摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-Bis(bromomethyl)-6,7-dimethoxyquinoxaline | 33561-34-1

中文名称
——
中文别名
——
英文名称
2,3-Bis(bromomethyl)-6,7-dimethoxyquinoxaline
英文别名
Quinoxaline, 2,3-bis(bromomethyl)-6,7-dimethoxy-
2,3-Bis(bromomethyl)-6,7-dimethoxyquinoxaline化学式
CAS
33561-34-1
化学式
C12H12Br2N2O2
mdl
——
分子量
376.047
InChiKey
CUUNBRSTYACOSY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    405.3±40.0 °C(Predicted)
  • 密度:
    1.733±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    18
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    44.2
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2,3-Bis(bromomethyl)-6,7-dimethoxyquinoxaline哌啶 作用下, 以 甲醇 为溶剂, 反应 18.5h, 生成 1,4-Dimethoxy-7,8-dimethyl-6,9-dipyridiniophenazine dibromide
    参考文献:
    名称:
    Synthesis of some substituted quinoxalines and polycyclic systems containing the quinoxaline nucleus
    摘要:
    所述的合成包括作为中间体的喹唑啉11、14、15、16、20、21、23和25。讨论了从3通过硫脲作用制备21以及从硫化物20和正丁胺形成六氮五元环23的过程。重新研究了二酮10的甲基化,发现产物为29和30的混合物。描述了二甲氧基喹唑啉穴合配体(如32、33、34、40和41)、三环冠醚31和五环冠醚(如38)的制备,并报道了金属离子对40和41光谱性质的影响。
    DOI:
    10.1039/p19960002443
  • 作为产物:
    描述:
    1,2-二甲氧基-4-二硝基苯 在 palladium on activated charcoal 氢气 作用下, 以 为溶剂, 反应 1.0h, 生成 2,3-Bis(bromomethyl)-6,7-dimethoxyquinoxaline
    参考文献:
    名称:
    Potent quinoxaline-spaced phosphono .alpha.-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation
    摘要:
    A series of alpha-amino-3-(phosphonoalkyl)-2-quinoxalinepropanoic acids was synthesized and evaluated for NMDA receptor affinity using a[H-3]CPP binding assay. Functional antagonism of the NMDA receptor complex was evaluated in vitro using a stimulated [H-3]TCP binding assay and in vivo by employing an NMDA-induced seizure model. Some analogues also were evaluated in the [H-3]-glycine binding assay. Several compounds of the AP-6 type show potent and selective NMDA antagonistic activity both in vitro and in vivo. In particular alpha-amino-7-chloro-3-(phosphonomethyl)-2-quinoxalinepropanoic acid (1) displayed an ED50 Of 1.1 mg/kg ip in the NMDA lethality model. Noteworthy is alpha-amino-6,7-dichloro-3-(phosphonomethyl)-2-quinoxalinepropanoic acid (3) with a unique dual activity, displaying in the NMDA receptor binding assay an IC50 of 3.4 nM and in the glycine binding assay an IC50 of 0.61 muM.
    DOI:
    10.1021/jm00055a004
点击查看最新优质反应信息

文献信息

  • US5118675A
    申请人:——
    公开号:US5118675A
    公开(公告)日:1992-06-02
  • [EN] QUINOXALINE PHOSPHONO-AMINO ACIDS
    申请人:——
    公开号:WO1992014740A1
    公开(公告)日:1992-09-03
    [FR] On décrit des composés de la formule (I) où Q représente le noyau de quinoxaline; m représente l'un des nombres entiers 0, 1 ou 2; n représente l'un des nombres entiers 1, 2 ou 3; ou un sel pharmaceutiquement acceptable, un ester d'alkyle ou (II) où R3 et R4 représentent indépendamment hydrogène, nitro, halo ou méthoxy. Ces composés sont des antagonistes de N-méthyle-D-Aspartate pouvant être utilisés pour le traitement et la prévention d'états pathologiques associés au système nerveux central et produits par une stimulation excessive des aminoacides excitateurs.
    [EN] The compounds of formula (I), in which Q is the quinoxaline nucleus; m is one of the integers 0, 1 or 2; n is one of the integers 1, 2 or 3; or a pharmaceutically acceptable salt, alkyl ester or (II) where R?3 and R?4 are, independently, hydrogen, nitro, halo or methoxy, are NMDA antagonists useful in the treatment and prevention of central nervous system related pathological conditions resulting from overstimulation by excitatory amino acids.
  • Synthesis of some substituted quinoxalines and polycyclic systems containing the quinoxaline nucleus
    作者:Abid R. Ahmad、Lina K. Mehta、John Parrick
    DOI:10.1039/p19960002443
    日期:——
    The synthesis is described of quinoxalines 11, 14, 15, 16, 20, 21, 23 and 25 of interest as intermediates. The preparation of 21 from 3 by the action of thiourea and the formation of the hexaazapentacycle 23 from sulfide 20 and butylamine are discussed. The methylation of the dione 10 is reinvestigated and the product found to be a mixture of 29 and 30. The preparation of dimethoxyquinoxaline podands, e.g., 32, 33, 34, 40 and 41, tricyclic crown ether 31 and pentacyclic crown ethers, e.g. 38, is described and the effects of metal ions on spectroscopic properties of 40 and 41 are reported.
    所述的合成包括作为中间体的喹唑啉11、14、15、16、20、21、23和25。讨论了从3通过硫脲作用制备21以及从硫化物20和正丁胺形成六氮五元环23的过程。重新研究了二酮10的甲基化,发现产物为29和30的混合物。描述了二甲氧基喹唑啉穴合配体(如32、33、34、40和41)、三环冠醚31和五环冠醚(如38)的制备,并报道了金属离子对40和41光谱性质的影响。
  • Potent quinoxaline-spaced phosphono .alpha.-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation
    作者:Reinhardt B. Baudy、Lynne P. Greenblatt、Ivo L. Jirkovsky、Mary Conklin、Ralph J. Russo、Donna R. Bramlett、Tracy A. Emrey、Joanne T. Simmonds、Dianne M. Kowal
    DOI:10.1021/jm00055a004
    日期:1993.2
    A series of alpha-amino-3-(phosphonoalkyl)-2-quinoxalinepropanoic acids was synthesized and evaluated for NMDA receptor affinity using a[H-3]CPP binding assay. Functional antagonism of the NMDA receptor complex was evaluated in vitro using a stimulated [H-3]TCP binding assay and in vivo by employing an NMDA-induced seizure model. Some analogues also were evaluated in the [H-3]-glycine binding assay. Several compounds of the AP-6 type show potent and selective NMDA antagonistic activity both in vitro and in vivo. In particular alpha-amino-7-chloro-3-(phosphonomethyl)-2-quinoxalinepropanoic acid (1) displayed an ED50 Of 1.1 mg/kg ip in the NMDA lethality model. Noteworthy is alpha-amino-6,7-dichloro-3-(phosphonomethyl)-2-quinoxalinepropanoic acid (3) with a unique dual activity, displaying in the NMDA receptor binding assay an IC50 of 3.4 nM and in the glycine binding assay an IC50 of 0.61 muM.
查看更多